Medicamen Biotech's FY26 saw consolidated revenue grow 21.66% to ₹197.77 Cr, with PAT jumping 49.43% to ₹9.80 Cr.

Medicamen Biotech LimitedMEDICAMEQ · Filed with the exchange

Domestic sales surged 71% via Medicamen Life Sciences.

Key developments include international expansion, CDMO wins, and oncology division growth.

The company incurred ₹1.18 Lakh in fines for compliance issues.

No comments yet. Be the first.

More from Medicamen Biotech Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.